Diagonal Therapeutics has clinched $125 million in an oversubscribed Series B fundraise, partly led by Sanofi Ventures, in a bid to advance its lead candidate for rare diseases into the clinic.
The Watertown, MA-based biotech …
Read More from Endpoints News